Prostaglandin I2 induces apoptosis via upregulation of Fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension

Archer, 2000, Primary pulmonary hypertension: a vascular biology and translational research “work in progress”, Circulation, 102, 2781, 10.1161/01.CIR.102.22.2781 Higenbottam, 1984, Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin), Lancet, 1, 1046, 10.1016/S0140-6736(84)91452-1 Miura, 2010, Three-dimensional structure of pulmonary capillary vessels in patients with pulmonary hypertension, Circulation, 121, 2151, 10.1161/CIR.0b013e3181e037c1 Runo, 2003, Primary pulmonary hypertension, Lancet, 361, 1533, 10.1016/S0140-6736(03)13167-4 Yuan, 2005, Pathogenesis of pulmonary arterial hypertension: the need for multiple hits, Circulation, 111, 534, 10.1161/01.CIR.0000156326.48823.55 Humbert, 2004, Treatment of pulmonary arterial hypertension, N Engl J Med, 351, 1425, 10.1056/NEJMra040291 Barst, 1996, A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group, N Engl J Med, 334, 296, 10.1056/NEJM199602013340504 Clapp, 2002, Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery, Am J Respir Cell Mol Biol, 26, 194, 10.1165/ajrcmb.26.2.4695 McLaughlin, 1998, Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension, N Engl J Med, 338, 273, 10.1056/NEJM199801293380501 McLaughlin, 2002, Survival in primary pulmonary hypertension: the impact of epoprostenol therapy, Circulation, 106, 1477, 10.1161/01.CIR.0000029100.82385.58 Sitbon, 2002, Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival, J Am Coll Cardiol, 40, 780, 10.1016/S0735-1097(02)02012-0 McLaughlin, 2006, Pulmonary arterial hypertension, Circulation, 114, 1417, 10.1161/CIRCULATIONAHA.104.503540 Akagi, 2010, Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension, Circ J, 74, 2200, 10.1253/circj.CJ-10-0190 Geraci, 2001, Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis, Circ Res, 88, 555, 10.1161/01.RES.88.6.555 Zhang, 2003, Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells, Am J Physiol Lung Cell Mol Physiol, 285, L740, 10.1152/ajplung.00284.2002 Ogawa, 2005, Prednisolone inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension, Circulation, 112, 1806, 10.1161/CIRCULATIONAHA.105.536169 Nakamura, 2010, Altered nano/micro-order elasticity of pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension, Int J Cardiol, 140, 102, 10.1016/j.ijcard.2008.11.022 Sato, 2000, Local mechanical properties measured by atomic force microscopy for cultured bovine endothelial cells exposed to shear stress, J Biomech, 33, 127, 10.1016/S0021-9290(99)00178-5 Bley, 2006, RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists, Br J Pharmacol, 147, 335, 10.1038/sj.bjp.0706554 Humbert, 2004, Cellular and molecular pathobiology of pulmonary arterial hypertension, J Am Coll Cardiol, 43, 13S, 10.1016/j.jacc.2004.02.029 Michelakis, 2006, Spatio-temporal diversity of apoptosis within the vascular wall in pulmonary arterial hypertension: heterogeneous BMP signaling may have therapeutic implications, Circ Res, 98, 172, 10.1161/01.RES.0000204572.65400.a5 Wharton, 2000, Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells, Circulation, 102, 3130, 10.1161/01.CIR.102.25.3130 Kunichika, 2004, Bosentan inhibits transient receptor potential channel expression in pulmonary vascular myocytes, Am J Respir Crit Care Med, 170, 1101, 10.1164/rccm.200312-1668OC Tantini, 2005, Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells, Basic Res Cardiol, 100, 131, 10.1007/s00395-004-0504-5 McMurtry, 2005, Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension, J Clin Invest, 115, 1479, 10.1172/JCI23203 McMurtry, 2004, Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis, Circ Res, 95, 830, 10.1161/01.RES.0000145360.16770.9f Nakamura, 2012, Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension, Int J Cardiol, 159, 100, 10.1016/j.ijcard.2011.02.024 Schermuly, 2005, Reversal of experimental pulmonary hypertension by PDGF inhibition, J Clin Invest, 115, 2811, 10.1172/JCI24838 Klein, 2008, Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling, Circulation, 118, 2081, 10.1161/CIRCULATIONAHA.108.779751 Perros, 2008, Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension, Am J Respir Crit Care Med, 178, 81, 10.1164/rccm.200707-1037OC Trauth, 1989, Monoclonal antibody-mediated tumor regression by induction of apoptosis, Science, 245, 301, 10.1126/science.2787530 Yonehara, 1989, A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor, J Exp Med, 169, 1747, 10.1084/jem.169.5.1747 Geng, 1997, Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells, Arterioscler Thromb Vasc Biol, 17, 2200, 10.1161/01.ATV.17.10.2200 Hatae, 2001, Prostacyclin-dependent apoptosis mediated by PPAR delta, J Biol Chem, 276, 46260, 10.1074/jbc.M107180200 Li, 2004, Prostacyclin induces apoptosis of vascular smooth muscle cells by a cAMP-mediated inhibition of extracellular signal-regulated kinase activity and can counteract the mitogenic activity of endothelin-1 or basic fibroblast growth factor, Circ Res, 94, 759, 10.1161/01.RES.0000121568.40692.97 Naderi, 2008, Activation of cAMP signaling enhances Fas-mediated apoptosis and activation-induced cell death through potentiation of caspase 8 activation, Hum Immunol, 69, 833, 10.1016/j.humimm.2008.09.005 Falcetti, 2010, Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension, Am J Respir Crit Care Med, 182, 1161, 10.1164/rccm.201001-0011OC Rich, 2010, Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension, Chest, 138, 1234, 10.1378/chest.09-2815